Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a Type II variation to the European Medicines Agency (EMEA) for marketing approval of Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B in adults. [click link for full article]
From: www.medicalnewstoday.com
Tenofovir Disoproxil Fumarate) For The Treatment Of ...
Posted by Ruslan Abuzant at 2:53 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment